Estée Lauder Companies
EL
$82.13
-0.86%
The Estée Lauder Companies is a global leader in the prestige beauty market, offering a diversified portfolio of skincare, makeup, fragrance, and haircare products under iconic brands such as Estée Lauder, Clinique, M.A.C, and La Mer. As a dominant player in the luxury beauty space, the company differentiates itself through its strong brand equity, extensive distribution network across 150+ countries, and a focus on premium innovation. The current investor narrative centers on the company's independent turnaround strategy after walking away from merger talks with Puig, with attention on its ability to stabilize revenue growth, improve margins, and navigate a challenging macroeconomic environment in key markets like Asia-Pacific.…
EL
Estée Lauder Companies
$82.13
Related headlines
EL 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Estée Lauder Companies's 12-month outlook, with a consensus price target around $95.15 and implied upside of +15.9% versus the current price.
Average Target
$95.15
0 analysts
Implied Upside
+15.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $125
Analyst target range
The stock is covered by 26 analysts, with a consensus recommendation of 'Buy' (mean rating of 2.36 on a scale where 1 is Strong Buy and 5 is Sell). The average target price is $95.31, implying approximately 16.0% upside from the current price of $82.13. The distribution of ratings is not explicitly provided, but the mean recommendation leans bullish, with several major firms like Citigroup (Buy), JP Morgan (Overweight), and UBS (Neutral) maintaining positive stances. Recent ratings actions show no downgrades, with firms reiterating their positions after the Q3 earnings release and the merger termination news.
The target price range spans from a low of $70.00 to a high of $125.00, indicating a wide dispersion of views. The high target of $125.00 assumes a successful turnaround with margin expansion and revenue acceleration, potentially driven by new product launches and market share gains in Asia. The low target of $70.00 prices in continued headwinds from travel retail weakness, competitive pressure, and potential further margin compression. The spread of $55 between low and high reflects high uncertainty about the company's recovery trajectory. The consensus EPS estimate for the current fiscal year is $4.90, which would represent a dramatic rebound from the trailing loss, underscoring the binary nature of the investment thesis.
Drowning in data?
Find the real signal!
Bulls vs Bears: EL Investment Factors
Estée Lauder presents a high-risk, high-reward turnaround story. The bull case rests on a strong brand portfolio, low valuation relative to history and peers, positive free cash flow, and expected earnings recovery to $4.90 EPS. The bear case highlights severe price decline, high debt, negative trailing earnings, and dependence on volatile Asian markets. Currently, the bearish evidence is stronger given the persistent downtrend and margin pressure, but the low valuation and analyst upside potential offer a compelling contrarian opportunity. The single most important tension is whether the company can execute its independent turnaround plan to restore revenue growth and margins, which would validate the bullish thesis and drive the stock toward the average target of $95.31.
Bullish
- Strong Brand Portfolio and Global Reach: Estée Lauder owns iconic brands like Estée Lauder, Clinique, M.A.C, and La Mer, operating in over 150 countries. This diversification provides resilience and pricing power, with skincare (49% of sales) as a key growth driver.
- Significant Upside to Analyst Targets: The average analyst target price of $95.31 implies a 16.0% upside from the current price of $82.13. With a consensus 'Buy' rating from 26 analysts, the market sees potential for recovery.
- Low Valuation vs. History and Peers: The trailing P/S ratio of 2.04 is near historical lows and below the industry average of ~2.5, representing an 18.4% discount. The PEG ratio of 0.07 suggests undervaluation relative to expected earnings growth.
- Positive Free Cash Flow Generation: Trailing twelve-month free cash flow is $1.285 billion, providing a cushion for debt service and dividends. Operating cash flow of $412 million in Q3 FY2026 covered capital expenditures of $102 million.
Bearish
- Severe Stock Price Decline and Momentum: The stock has fallen 511.78% over the past year and is down 40.02% in the last month alone. The sustained downtrend and underperformance vs. the S&P 500 (relative strength -2346.78% over 1 year) signal persistent selling pressure.
- High Debt and Leverage Concerns: Debt-to-equity ratio of 2.44 is elevated, and interest expense of $82 million per quarter weighs on profitability. The quick ratio of 0.94 indicates potential liquidity strain.
- Negative Trailing Earnings and Thin Margins: Trailing twelve-month EPS is -$0.04, and net margin is only 2.4% in Q3 FY2026. Operating margin of 6.7% is well below historical levels, reflecting high SG&A expenses of $2.279 billion.
- Dependence on Volatile Travel Retail and Asia: Asia-Pacific accounts for 32% of revenue, and travel retail exposure adds volatility. Recent weakness in these channels has pressured sales, and recovery is uncertain.
EL Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of -511.78%, reflecting a severe decline from its 52-week high of $121.64 to the current price of $82.13, which is only 67.5% of the 52-week range. This positioning near the lower end of the range suggests the stock is deeply oversold, but the persistent downtrend indicates that buying pressure has been insufficient to reverse the bearish momentum. The 52-week low of $66.22, reached in March 2026, represents a critical support level, and the current price is 24% above that low, offering a potential floor if fundamentals stabilize.
Short-term momentum shows a mixed picture: the 1-month price change is -40.02%, indicating a sharp recent decline, while the 3-month change is +7.78%, suggesting a modest recovery from the March lows. This divergence implies that while the stock has attempted to bounce, the recent selloff has erased those gains, pointing to persistent selling pressure. The relative strength versus the S&P 500 is deeply negative over 1-month (-71.02%) and 1-year (-2346.78%), confirming that EL is significantly underperforming the broader market. The beta of 1.261 indicates the stock is 26.1% more volatile than the market, amplifying both downside and upside moves.
Key technical levels include resistance at the 52-week high of $121.64 and support at the 52-week low of $66.22. A breakout above $121.64 would signal a potential trend reversal, while a breakdown below $66.22 could accelerate losses toward new lows. The stock's high beta of 1.261 means it is more sensitive to market swings, and the current volatility, with a max drawdown of -43.79%, underscores the risk of further downside. Volume data shows average daily volume of 2.45 million shares, indicating active trading but not panic selling.
Beta
1.26
1.26x market volatility
Max Drawdown
-43.8%
Largest decline past year
52-Week Range
$66-$122
Price range past year
Annual Return
-5.1%
Cumulative gain past year
| Period | EL Return | S&P 500 |
|---|---|---|
| 1m | -0.4% | -0.5% |
| 3m | +7.8% | +4.9% |
| 6m | -28.6% | +9.7% |
| 1y | -5.1% | +18.4% |
| ytd | -23.1% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EL Fundamental Analysis
Revenue in the most recent quarter (Q3 FY2026, ended March 31, 2026) was $3.712 billion, up 4.56% year-over-year, marking a modest recovery from the prior year's decline. However, the multi-quarter trend shows revenue deceleration: Q2 FY2026 revenue was $4.238 billion, down from $4.004 billion in Q2 FY2025, and Q1 FY2026 revenue of $3.481 billion was up only 3.6% from $3.361 billion a year earlier. The revenue segments reveal that skincare (49% of sales) is the primary driver, contributing $1.856 billion in the quarter, while makeup ($1.072 billion) and fragrance ($628 million) also support growth. The company's reliance on travel retail and Asia-Pacific (32% of revenue) remains a vulnerability, as those channels have been volatile.
The company is marginally profitable, with net income of $89 million in Q3 FY2026, a significant improvement from a net loss of $546 million in Q4 FY2025. Gross margin stands at 71.04%, relatively stable and typical for the premium beauty industry, but operating margin is thin at 6.7%, reflecting high selling, general, and administrative expenses of $2.279 billion. The net margin of 2.4% is below historical levels, indicating that cost pressures and restructuring charges are weighing on profitability. The trailing twelve-month EPS is -$0.04, but the forward EPS estimate of $4.90 suggests a sharp turnaround is expected by analysts.
The balance sheet shows a debt-to-equity ratio of 2.44, indicating significant leverage, which is common in the industry but elevated. Free cash flow for the trailing twelve months is $1.285 billion, providing some cushion for debt service and dividends. The current ratio of 1.30 suggests adequate liquidity, though the quick ratio of 0.94 indicates potential strain on short-term obligations. Return on equity is deeply negative at -29.3%, reflecting the impact of recent losses on shareholder equity. The company generated $412 million in operating cash flow in Q3 FY2026, covering capital expenditures of $102 million, but the high debt load (interest expense of $82 million per quarter) remains a concern.
Quarterly Revenue
$3.7B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
71.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EL Overvalued?
Since net income is negative on a trailing basis (TTM EPS of -$0.04), the trailing P/E ratio is not meaningful. Therefore, we use the price-to-sales (P/S) ratio as the primary valuation metric. The trailing P/S ratio is 2.04, while the forward P/S (based on estimated revenue of $17.3 billion) is approximately 1.68. The gap between trailing and forward P/S implies that the market expects revenue growth to continue, justifying a slightly higher multiple on future sales. The PEG ratio of 0.07 is extremely low, suggesting that the stock is undervalued relative to its expected earnings growth, but this metric should be treated with caution given the negative trailing earnings.
Compared to the household & personal products industry average P/S ratio of approximately 2.5 (based on sector data), EL's trailing P/S of 2.04 represents a 18.4% discount. This discount may be justified by the company's recent earnings volatility and negative net income, as well as its higher debt levels. However, EL's strong brand portfolio and global scale could warrant a premium if profitability recovers. The forward P/S of 1.68 further widens the discount, indicating that the market is pricing in continued challenges.
Historically, EL's P/S ratio has ranged from a low of around 1.5 in early 2026 to a high of over 24 in 2021. The current P/S of 2.04 is near the bottom of its historical range, suggesting that the stock is trading at a significant discount to its own past valuations. This could indicate a value opportunity if the company's fundamentals improve, but it also reflects the market's skepticism about near-term growth and margin recovery. The P/B ratio of 7.53 is also near historical lows, further supporting the view that the stock is cheap on a book value basis.
PE
-25.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 28x~169x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
184.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Estée Lauder carries a high debt-to-equity ratio of 2.44, with quarterly interest expense of $82 million that consumes a significant portion of operating income. The company's net margin of 2.4% in Q3 FY2026 is razor-thin, and trailing twelve-month EPS is negative at -$0.04, indicating that profitability has not yet stabilized. Free cash flow of $1.285 billion provides some buffer, but the quick ratio of 0.94 suggests potential difficulty meeting short-term obligations if cash flow deteriorates. Revenue growth of 4.56% YoY in Q3 is modest, and the company's reliance on travel retail and Asia-Pacific (32% of sales) exposes it to regional volatility.
Market & Competitive Risks: The stock's beta of 1.261 indicates 26.1% higher volatility than the market, amplifying downside risk in a downturn. The trailing P/S of 2.04, while below the industry average of 2.5, may still be vulnerable to compression if the company fails to deliver on earnings expectations. Competitive pressure from L'Oréal and other prestige beauty players could erode market share, especially in key categories like skincare. The recent termination of merger talks with Puig introduces uncertainty about the company's strategic direction, though the market initially reacted positively to the independent turnaround plan.
Worst-Case Scenario: If the company's turnaround fails to gain traction, revenue growth stalls, and margins remain compressed, the stock could fall to its 52-week low of $66.22, representing a 19.4% decline from the current price of $82.13. In a more severe scenario, continued losses and debt covenant breaches could drive the stock below $66.22, potentially testing the $60 level. This would imply a loss of up to 27% from current levels, consistent with the analyst low target of $70.00 and the stock's historical max drawdown of -43.79%.
